1. Home
  2. SNN vs PODD Comparison

SNN vs PODD Comparison

Compare SNN & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith & Nephew SNATS Inc.

SNN

Smith & Nephew SNATS Inc.

HOLD

Current Price

$33.95

Market Cap

14.3B

Sector

Health Care

ML Signal

HOLD

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$204.80

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNN
PODD
Founded
1856
2000
Country
United Kingdom
United States
Employees
16988
N/A
Industry
Industrial Specialties
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3B
17.0B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
SNN
PODD
Price
$33.95
$204.80
Analyst Decision
Hold
Buy
Analyst Count
2
20
Target Price
$36.25
$347.55
AVG Volume (30 Days)
696.1K
775.0K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.20%
N/A
EPS Growth
N/A
N/A
EPS
N/A
3.48
Revenue
N/A
$2,708,100,000.00
Revenue This Year
$8.61
$24.59
Revenue Next Year
$5.60
$19.18
P/E Ratio
$64.97
$58.10
Revenue Growth
N/A
30.73
52 Week Low
$25.45
$194.61
52 Week High
$38.79
$354.88

Technical Indicators

Market Signals
Indicator
SNN
PODD
Relative Strength Index (RSI) 56.59 36.58
Support Level $32.03 N/A
Resistance Level $37.23 $299.75
Average True Range (ATR) 0.56 6.04
MACD 0.32 0.94
Stochastic Oscillator 78.35 42.65

Price Performance

Historical Comparison
SNN
PODD

About SNN Smith & Nephew SNATS Inc.

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Share on Social Networks: